Meeting Information
Course Directors
Faculty
- International Faculty
- Korean Faculty
Focus
Scientific Program
• Meeting at a Glance
• Program
  - Main Arena
  - Coronary Arena
  - Endovascular Arena
  - Symposium Arena
  - Tutorial Arena
  - Breakfast Meetings
  - Satellite Symposia
  - Oral Abstract Presentation
  - Case Presentation
  - Live Case Operators
  - Conference for
    Cardiovascular Nurse
    & Technologist
  - Cardiopulmonary
     Rehabilitation Workshop
  - Clinical Exercise
    Specialist (CES) Workshop
Live Case Demonstration
E-Poster Abstracts
Live Case Transmission
    Sites
Factoid
Syllabus
Summit Live Interview
Gallery
Daily Newspaper
Advance Registration
Housing
Exhibition
- Exhibition Information
- Exhibitor's List & Floor Plan
Learning Center
Eco-Friendly Convention
     : Yes, Green!
Tour Information
- Korea, Sparkling
- About Seoul
- Visa
- Tour Program
Contact Us
About CVRF
2009 Brochure Download




Wednesday, April 22, 2009   
Grand Opening
"Angioplasty Summit-TCT Asia Pacific 2009"
The opening of the 14th "Angioplasty Summit 2009-TCT Asia Pacific" has been announced with hundreds of specialists and experts gathered at the Main Arena, Sheraton Grande Walkerhill Hotel, Seoul, Korea on April 22.

This meeting provides a unique opportunity to gather with colleagues from around the world in an educational and professional environment. Angioplasty Summit-TCT Asia Pacific is a scientific and international investigations as well. The conference consists of live demonstrations and the state of-art lectures by experts from all over the world and has over about 2,500 participants from the globe......
What's New in 2009!!!
• Left Main & Bifurcation Summit
• Imaging & Physiology Summit
• Structural Heart Disease Symposium
• Review Course for Young Interventionists, Cardiothoracic & Vascular Surgeon
• How to Make Good Clinical Trials Session
• Moderated Abstract and Case Presentation Sessions
• The 3rd Cardiopulmonary Rehabilitation Workshop......
Are There Ongoing Risks with DES?
Drug-eluting stents (DES) have largely demonstrated their superiority to baremetal stents (BMS) in preventing ins tent res tenos i s . Since they have received marketing approval from the Food and Drug Administration in 2003, the widespread utilization of DES in randomized controlled trials is more common and their clinical use in the
Uni ted States has been increasing progressively. The safety of DES was questioned for the first time in September 2006 at the meeting of the European Society of Cardiology, at which a meta-analysis was presented, reporting a statistically significant increase in mortality and nonfatal myocardial infarction at 2-3 years in patients who had received a sirolimus-eluting stent. After that, the concern shifted to the issue of stent thrombosis (ST) , which, whi le very inf requent , resul t s in a ver y poor prognosis, mandating prolonged dual ant iplatelet therapy , and led to a decrease in use of the first-generation DES and the development of a safer and more effective second-generation......